This activity is supported by educational grants from the Bristol-Myers Squibb and Pfizer Alliance; and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
NPs and PAs in primary care
Upon completion of this activity, participants should be able to:
Discuss the safety and efficacy profiles for DOACs vs warfarin in patients with obesity
Develop a treatment plan for a patient with VTE and obesity utilizing the most recent clinical evidence, expert consensus recommendations, and patient specific factors
Assess risk factors for VTE recurrence and bleeding to determine the appropriate length of therapy for VTE treatment in a patient with obesity
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Ruff: consultant/advisor/speaker: Anthos, Bayer, Bristol-Myers Squibb, Janssen, Pfizer; researcher: Anthos, AstraZeneca, National Institutes of Health; researcher/consultant/advisor/speaker: Boehringer Ingelheim, Daiichi Sankyo.
Mr Thibodeau: has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
Release date: April 15, 2022
Expiration date: April 14, 2023
Interactive, audio-enhanced slide lecture
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program has been made available online.